Compare INSE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | RLYB |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.6M | 88.0M |
| IPO Year | 2014 | 2021 |
| Metric | INSE | RLYB |
|---|---|---|
| Price | $4.40 | $15.76 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.85 | N/A |
| AVG Volume (30 Days) | ★ 552.5K | 24.9K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.64 |
| Revenue | ★ $199,800,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | ★ N/A | $2.76 |
| Revenue Growth | 30.25 | ★ 43.00 |
| 52 Week Low | $3.10 | $0.56 |
| 52 Week High | $9.95 | $32.54 |
| Indicator | INSE | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 42.74 |
| Support Level | $3.31 | $7.93 |
| Resistance Level | $8.42 | $16.89 |
| Average True Range (ATR) | 0.31 | 1.79 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 80.38 | 2.78 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.